Ritsu Kuno, MD
Pulmonary Disease · Richmond, VANPI 1114950391
Payments from drug & device makers
Across 469 payments — averaging $136.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$31K
- Merck$26K
- GSK$2K
- Sanofi$661
- Genentech USA, Inc.$652
- Boehringer Ingelheim$457
- plus $3K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $30,775 |
| Merck | 10 | $26,416 |
| GSK | 136 | $1,967 |
| Sanofi | 34 | $661 |
| Genentech USA, Inc. | 50 | $652 |
| Boehringer Ingelheim | 21 | $457 |
| Regeneron Healthcare Solutions, Inc. | 19 | $333 |
| Amgen | 12 | $263 |
| Insmed, Inc. | 14 | $236 |
| Mylan Specialty L.p. | 14 | $210 |
| Grifols USA, LLC | 10 | $201 |
| Electromed, Inc. | 6 | $187 |
| Inogen, Inc. | 8 | $164 |
| Actelion Pharmaceuticals US, Inc. | 7 | $145 |
| Paratek Pharmaceuticals, Inc. | 8 | $141 |
| Vifor Pharma, Inc. | 7 | $127 |
| Novartis | 7 | $102 |
| Mallinckrodt Hospital Products Inc. | 4 | $94 |
| Philips North America LLC | 6 | $92 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Pulmonx Corporation | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| United Therapeutics Corporation | 4 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $61 |
| Zealand Pharma US, Inc. | 3 | $59 |
| Intuitive Surgical | 1 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Verona Pharma, Inc. | 2 | $34 |
| Atricure, Inc. | 1 | $34 |
| Pharming Healthcare, Inc. | 2 | $32 |
| Pfizer | 1 | $26 |
| Covis Pharma GmbH | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Valeritas, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
How this compares
$63,979 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Richmond
- Shilpa JohriRichmond$1.7M
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Ray ShepherdRichmond$303K
- Sujoy GillRichmond$296K
- Glenn GiesselRichmond$267K
- Marjolein DewitRichmond$214K
- Nauman ChaudaryRichmond$77K
- Daniel GrinnanRichmond$45K
- Kenneth HaftRichmond$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.